Literature DB >> 15761498

The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury.

Christian Klein1, Torsten Wüstefeld, Ulrike Assmus, Tania Roskams, Stefan Rose-John, Michael Müller, Michael P Manns, Mattias Ernst, Christian Trautwein.   

Abstract

Increasing evidence demonstrates that IL-6 has a protective role during liver injury. IL-6 activates intracellular pathways via the gp130 receptor. In order to identify IL-6-gp130 pathways involved in mediating liver protection, we analyzed hepatocyte-specific gp130 knockout mice in a concanavalin A-induced (Con A-induced) model of immune-mediated hepatitis. We demonstrated that IL-6-gp130-dependent pathways in hepatocytes alone are sufficient for triggering protection in Con A-induced hepatitis. gp130-STAT3 signaling in hepatocytes mediates the IL-6-triggered protective effect. This was demonstrated by analysis of IL-6-induced protection in mice selectively deficient for gp130-dependent STAT1/3 or gp130-SHP2-RAS signaling in hepatocytes. To identify IL-6-gp130-STAT1/3 dependently expressed liver-protective factors, we performed gene array analysis of hepatic gene expression in hepatocyte-specific gp130(-/-) mice as well as in gp130-STAT1/3- and gp130-SHP2-RAS-MAPK-deficient mice. The mouse IL-8 ortholog KC (also known as Gro-alpha) and serum amyloid A2 (SAA2) was identified as differentially IL-6-gp130-STAT3-regulated genes. Hepatic expression of KC and SAA2 mediate the liver-protective potential of IL-6, since treatment with recombinant KC or serum SAA2 effectively reduced liver injury during Con A-induced hepatitis. In summary, this study defines IL-6-gp130-STAT3-dependent gene expression in hepatocytes that mediates IL-6-triggered protection in immune-mediated Con A-induced hepatitis. Additionally, we identified the IL-6-gp130-STAT3-dependent proteins KC and SAA2 as new candidates for therapeutic targets in liver diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761498      PMCID: PMC1059450          DOI: 10.1172/JCI23640

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A.

Authors:  Q Cao; R Batey; G Pang; A Russell; R Clancy
Journal:  Immunol Cell Biol       Date:  1998-12       Impact factor: 5.126

2.  Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice.

Authors:  K Kovalovich; R A DeAngelis; W Li; E E Furth; G Ciliberto; R Taub
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

3.  Adsorption, simple binding and complex binding of rat hepatocytes to various in vitro substrata.

Authors:  R Gjessing; P O Seglen
Journal:  Exp Cell Res       Date:  1980-09       Impact factor: 3.905

4.  Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis.

Authors:  Claudine S Bonder; Maureen N Ajuebor; Lori D Zbytnuik; Paul Kubes; Mark G Swain
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

5.  IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners.

Authors:  Rui Sun; Zhigang Tian; Shalini Kulkarni; Bin Gao
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats.

Authors:  Matilde Bustos; Naiara Beraza; Juan-Jose Lasarte; Elena Baixeras; Pilar Alzuguren; Thierry Bordet; Jesus Prieto
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

7.  ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism.

Authors:  Christian Klein; Torsten Wüstefeld; Peter C Heinrich; Konrad L Streetz; Michael P Manns; Christian Trautwein
Journal:  Eur J Immunol       Date:  2003-08       Impact factor: 5.532

8.  Lack of gp130 expression in hepatocytes promotes liver injury.

Authors:  Konrad L Streetz; Torsten Wüstefeld; Christian Klein; Karl-Josef Kallen; Francois Tronche; Ullrich A K Betz; Günther Schütz; Michael P Manns; Werner Müller; Christian Trautwein
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Immune mechanisms for hepatic fibrogenesis. T-lymphocyte-mediated stimulation of fibroblast collagen production in chronic active hepatitis.

Authors:  A Casini; O E Ricci; F Paoletti; C Surrenti
Journal:  Liver       Date:  1985-06

Review 10.  Acquiring signalling specificity from the cytokine receptor gp130.

Authors:  Matthias Ernst; Brendan J Jenkins
Journal:  Trends Genet       Date:  2004-01       Impact factor: 11.639

View more
  70 in total

Review 1.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

2.  Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice.

Authors:  A L Gavito; R Cabello; J Suarez; A Serrano; F J Pavón; M Vida; M Romero; V Pardo; D Bautista; S Arrabal; J Decara; A L Cuesta; A M Valverde; F Rodríguez de Fonseca; E Baixeras
Journal:  Br J Pharmacol       Date:  2016-02-22       Impact factor: 8.739

3.  Heat stress stimulates hepcidin mRNA expression and C/EBPα protein expression in aged rodent liver.

Authors:  Steven A Bloomer; Kevin C Kregel; Kyle E Brown
Journal:  Arch Gerontol Geriatr       Date:  2013-08-08       Impact factor: 3.250

4.  Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases.

Authors:  Silvio Danese; Bin Gao
Journal:  Gut       Date:  2010-02       Impact factor: 23.059

5.  Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway.

Authors:  Benting Ma; Junjie Zhu; Juan Tan; Yulei Mao; Lingyun Tang; Chunling Shen; Hongxing Zhang; Ying Kuang; Jian Fei; Xiao Yang; Zhugang Wang
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

6.  A model of liver regeneration.

Authors:  Leon A Furchtgott; Carson C Chow; Vipul Periwal
Journal:  Biophys J       Date:  2009-05-20       Impact factor: 4.033

7.  Chlamydia trachomatis infection modulates trophoblast cytokine/chemokine production.

Authors:  Eugenia de la Torre; Melissa J Mulla; Andrew G Yu; Seung-Joon Lee; Paula B Kavathas; Vikki M Abrahams
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

8.  JUNB/AP-1 controls IFN-γ during inflammatory liver disease.

Authors:  Martin K Thomsen; Latifa Bakiri; Sebastian C Hasenfuss; Rainer Hamacher; Lola Martinez; Erwin F Wagner
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

9.  Acute and chronic effects of IL-22 on acetaminophen-induced liver injury.

Authors:  Dechun Feng; Yan Wang; Hua Wang; Honglei Weng; Xiaoni Kong; Brittany V Martin-Murphy; Yongmei Li; Ogyi Park; Steven Dooley; Cynthia Ju; Bin Gao
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

10.  IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality.

Authors:  Hong Zhang; Patrick Neuhöfer; Liang Song; Björn Rabe; Marina Lesina; Magdalena U Kurkowski; Matthias Treiber; Thomas Wartmann; Sara Regnér; Henrik Thorlacius; Dieter Saur; Gregor Weirich; Akihiko Yoshimura; Walter Halangk; Joseph P Mizgerd; Roland M Schmid; Stefan Rose-John; Hana Algül
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.